September 19, 2022

TB Alliance Board of Directors Appoints Two New Members

Kim Schwartz and Rasha Hibri are Welcomed to the Board
August 31, 2022

Drug-Resistant TB Trial Results Published in New England Journal of Medicine

Results of ZeNix Trial Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing of Linezolid
August 17, 2022

PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials

Public-private collaboration to evaluate five antimicrobial agents across two combination regimens for treating both drug-susceptible and drug-resistant forms of TB with shorter treatment durations
June 1, 2022

TB Alliance Names Pietro Turilli as Head of External Affairs

Executive brings more than 20 years in global partnerships and resource mobilization
March 24, 2022

Advancing the Treatment of Drug-Resistant Tuberculosis this World TB Day

Imagining a TB-free world amidst resurgence during COVID-19 pandemic
February 2, 2022

TB Alliance Names Maria Beumont as Vice President, Chief Medical Officer for Research and Development

Executive brings more than 20 years of experience in pharmaceutical development